For some medical conditions there are hundreds of bacteria shifts reported, for others only a few. The Percentage is based on the least number. If there are matches 8 matches for a condition that has 10 known bacteria shifts, against a condition that has 50 bacteria shifts. It will be 8/10 or 80% and not 8/50= 16%. The count of possible bacteria is shown for reference.
Limited to conditions with 5 or more bacteria
Name | Overlap Percent | Prevalance in Population | Matches | Bacteria in From | Bacteria in To |
---|---|---|---|---|---|
Autism | 55.5 % | 2% | 61 | 110 | 267 |
Alzheimer's disease | 72 % | 10% | 36 | 50 | 267 |
Ulcerative colitis | 55.6 % | 0.1% | 60 | 108 | 267 |
Allergies | 44 % | 30% | 22 | 50 | 267 |
Schizophrenia | 44.1 % | 0.75% | 41 | 93 | 267 |
Mood Disorders | 66.7 % | 29.7% | 4 | 6 | 267 |
Ankylosing spondylitis | 35.6 % | 7% | 95 | 520 | 267 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 47.8 % | 0.86% | 64 | 134 | 267 |
Rosacea | 45.5 % | 5.46% | 10 | 22 | 267 |
Psoriasis | 56.5 % | 3% | 26 | 46 | 267 |
Multiple Sclerosis | 51 % | 0.5% | 51 | 100 | 267 |
Obesity | 38.5 % | 42.4% | 40 | 104 | 267 |
Osteoporosis | 50 % | 9.4% | 11 | 22 | 267 |
neuropsychiatric disorders (PANDAS, PANS) | 46.7 % | 0.1% | 7 | 15 | 267 |
Obesity | 78.2 % | 42.4% | 43 | 55 | 267 |
ME/CFS without IBS | 46.2 % | 0.4% | 12 | 26 | 267 |
Multiple system atrophy (MSA) | 47.6 % | 0.005% | 10 | 21 | 267 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 51.2 % | 0.005% | 22 | 43 | 267 |
Metabolic Syndrome | 85.7 % | 21% | 6 | 7 | 267 |
ME/CFS with IBS | 52.6 % | 2.8% | 10 | 19 | 267 |
Liver Cirrhosis | 50.9 % | 0.27% | 136 | 678 | 267 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 46.1 % | 25% | 35 | 76 | 267 |
Chronic Kidney Disease | 68.6 % | 15% | 24 | 35 | 267 |
Systemic Lupus Erythematosus | 56.1 % | 0.15% | 37 | 66 | 267 |
Depression | 45.7 % | 8% | 37 | 81 | 267 |
Parkinson's Disease | 44.4 % | 1% | 40 | 90 | 267 |
IgA nephropathy (IgAN) | 41.4 % | 0.001% | 12 | 29 | 267 |
Hyperlipidemia (High Blood Fats) | 48 % | 33% | 12 | 25 | 267 |
Insomnia | 90 % | 30% | 9 | 10 | 267 |
hypertension (High Blood Pressure | 83.3 % | 47% | 5 | 6 | 267 |
Irritable Bowel Syndrome | 50 % | 15% | 31 | 62 | 267 |
Allergic Rhinitis (Hay Fever) | 33.3 % | 7.8% | 12 | 36 | 267 |
gallstone disease (gsd) | 73.3 % | 5% | 11 | 15 | 267 |
Chronic Urticaria (Hives) | 56.5 % | 5% | 13 | 23 | 267 |
Graves' disease | 25 % | 0.5% | 2 | 8 | 267 |
hypercholesterolemia (High Cholesterol) | 44.4 % | 12% | 4 | 9 | 267 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 37.5 % | 27.8% | 9 | 24 | 267 |
Functional constipation / chronic idiopathic constipation | 51.2 % | 14% | 21 | 41 | 267 |
Gout | 19 % | 6.8% | 4 | 21 | 267 |
Epilepsy | 56 % | 0.84% | 14 | 25 | 267 |
Fibromyalgia | 56.8 % | 1.12% | 21 | 37 | 267 |
Inflammatory Bowel Disease | 56.1 % | 1.3% | 37 | 66 | 267 |
Type 1 Diabetes | 67.3 % | 0.19% | 35 | 52 | 267 |
cystic fibrosis | 14.3 % | 0.03% | 1 | 7 | 267 |
COVID-19 | 33.3 % | 50% | 12 | 36 | 267 |
Cerebral Palsy | 76.5 % | 0.2% | 13 | 17 | 267 |
Colorectal Cancer | 24.3 % | 4.3% | 65 | 296 | 267 |
Chronic Fatigue Syndrome | 49.1 % | 3% | 27 | 55 | 267 |
Celiac Disease | 53.7 % | 1.4% | 36 | 67 | 267 |
Coronary artery disease | 43.8 % | 6.7% | 7 | 16 | 267 |
Carcinoma | 72.5 % | 1% | 37 | 51 | 267 |
Barrett esophagus cancer | 31.3 % | 7% | 5 | 16 | 267 |
Bipolar Disorder | 60.6 % | 3% | 20 | 33 | 267 |
Asthma | 40.7 % | 8% | 11 | 27 | 267 |
Atherosclerosis | 37.8 % | 50% | 101 | 524 | 267 |
Acne | 68.4 % | 47% | 13 | 19 | 267 |
Crohn's Disease | 57.4 % | 0.3% | 81 | 141 | 267 |
Generalized anxiety disorder | 42.9 % | 2.7% | 6 | 14 | 267 |
Small Intestinal Bacterial Overgrowth (SIBO) | 37.5 % | 52% | 6 | 16 | 267 |
Sjögren syndrome | 61 % | 1.2% | 25 | 41 | 267 |
Stress / posttraumatic stress disorder | 62.5 % | 5.2% | 35 | 56 | 267 |
ADHD | 55.3 % | 9.4% | 26 | 47 | 267 |
Hashimoto's thyroiditis | 50 % | 0.35% | 7 | 14 | 267 |
Brain Trauma | 68.2 % | 0.367% | 15 | 22 | 267 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 ยงโฏ1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.